Case series:Apatinib combined with docetaxel

2 trials

Sponsors

The People's Hospital of Tongliang District, Chongqing, Shanxi Tumor Hospital

Conditions

Lung adenocarcinoma without driver gene mutationgastric cancer

Phase 4

Clinical study of Apatinib combined with docetaxel as second-line treatment in advanced gastric cancer

RecruitingChiCTR-OPC-17013834

Shanxi Tumor Hospitalgastric cancer

Start: 2017-03-30Updated: 2017-12-18

One-arm, single-center, open-label clinical study of lapatinib mesylate combined with docetaxel in the treatment of lung adenocarcinoma with no driver gene mutation

Active, not recruitingChiCTR1800018500

The People's Hospital of Tongliang District, ChongqingLung adenocarcinoma without driver gene mutation

Start: 2018-10-01Updated: 2018-09-24

Related Papers

Clinical efficacy and safety of apatinib combined with docetaxel in second-line treatment for advanced gastric cancer: A prospective study.

Journal of Clinical Oncology2018-05-20